CMBG Announces Positive Phase I Result

Cellular Biomedicine Group Announces Positive Phase I Result
Stock Increases 163% since Low in April

Los Angeles, May 26, 2015 -- StockWatchIndex today publishes the latest Cellular Biomedicine Group Inc. (CBMG) news.  CBMG was added to the SWI WatchIndex on March 12, 2015. Since then the stock has recovered from its low of $22.33 on April 8, 2015 to $36.99 at the close of market on Friday, May 22, 2105, an increase of 165%. 
SHANGHAI, China and PALO ALTO, Calif., May 22, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (CBMG), a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced encouraging clinical data from its Chimeric Antigen Receptor (CAR-T) CD30-positive Hodgkin's lymphoma immuno-oncology clinical development program. The results of this trial to date demonstrated that five out of seven patients responded to the treatment. CD30-directed CAR-T cell therapy was demonstrated in this trial to be safe, feasible and efficient. The data was presented by Dr. William (Wei) Cao, PhD, BM, Chief Executive Officer of Cellular Biomedicine Group, at the 10th Annual World Stem Cells & Regenerative Medicine Congress in London, UK on May 21, 2015.

Further details of the clinical data may be viewed in the Company's most recent presentation filed on Form 8k with the SEC, which can be found on the Company's website at the following link: under SEC filings or presentations.

About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility in China, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit:

To see an interview with Dr. William (Wei) Cao, PhD, BM, Chief Executive Officer of Cellular Biomedicine Group (CBMG) on Wide World of Stocks go to Dr. Cao's interview follows a review of the current state of the Healthcare Sector with John McCAMANT, the editor of the Medical Technology Stock Letter.

Wide World of Stocks ( is a StockWatchindex Strategic Partner and is a print and digital content provider with multi-channel integration including television, radio, video, webcasts, podcasts and a magazine in both digital and print formats that delivers visibility to companies in the micro and small-cap sectors. The program has been seen in 100+ million homes, regionally and nationally on cable and major networks including CBS, NBC, ABC, and FOX

It may be safe to assume that the low in the CBMG stock price was at least partially caused by what CMPG calls "a putative securities class action lawsuit filed against the company". CMBG considers this lawsuit meritless and intends to vigorously defend against it. (
SWI is a leading edge PR, Information Marketing and Research firm with a highly frequented web site, its "Rise Above The Noise" newsletter and SWI Research site These services provide readers with information and research on new and promising public companies. The QuickPicks section on the SWI site represents the consolidated opinions of carefully selected financial analyst reports and opinions from credible Wall Street firms that we respect and frequently sample. The weekly SWI QuickPicks  Ratings Report keeps you informed about newly SWI initiated stocks and potential upgrades and downgrades in the QuickPicks section. We are not being compensated by these companies and do not necessarily hold positions in any of these stocks. You can conveniently follow the live links for each of these stocks on for more detail.  SWI's periodical "Portfolio Performance Report" frequently reports about the performance of the stocks that we have purchased and may be trading in the SWI portfolio. Please do not miss the wealth of frequently updated news, research reports and other valuable information elsewhere on SWI, especially for the stocks on our WatchIndex page. Watch a full range of CEO and analyst interviews on our Strategic Partner site 
Google +
Good luck and please pass this newsletter on to a friend
to continue building our community.

StockWatchIndex (SWI) is not a registered investment adviser and makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise) of the information provided in the publications for its Stock Watch List or on its web sites. The provided information is not to be construed as personal financial advice, or a solicitation to buy or sell stock. Some information has been generated by what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrants any results from use of the information. We have contracted with some of the companies we present on SWI or in the SWI Newsletter as public relations consultants to keep the market and especially our subscribers informed about the companies and may have been compensated in cash and/or stock and stock options. Principles of SWI may also hold positions in the stocks covered by SWI, which may be considered a potential conflict of interest. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in its Stock Watch List or in any of its other publications. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. StockWatchIndex expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. Please note that many of our publications contain "Forward Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and that actual results may differ materially from those statements.  The included information is subject to change without notice.

Copyright © 2015 StockWatchIndex, LLC, All rights reserved.

unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp